

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

XUANZHU BIOPHARM ENTERS INTO THE COOPERATIVE AGREEMENT IN RELATION TO COMBINATION THERAPIES WITH CTTQ-AKESO (SHANGHAI) BIOMED. TECH. CO., LTD.

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Co., Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物科技有限公司) (“**Xuanzhu Biopharm**”) of the Group has entered into the cooperative agreement in relation to combination therapies with CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (正大天晴康方(上海)生物醫藥科技有限公司) (“**CTTQ-Akeso**”), pursuant to which, both parties agreed to jointly carry out exploration and experiments on the AXL inhibitor of Xuanzhu Biopharm and the Penpulimab PD-1 monoclonal antibody of CTTQ-Akeso, with an aim of developing their application of combination therapies for solid tumors.

By taking full advantage of the expertise of Xuanzhu Biopharm in targeted therapies for tumors by small molecules and that of Akeso in immunotherapies for tumors by macromolecules, this cooperation will explore the application of combination immunotherapies in fields such as non-small cell lung cancer to benefit more cancer patients.

About CTTQ-Akeso

CTTQ-Akeso is a joint venture company jointly established by Chia-Tai Tianqing Pharmaceutical Group Co. Ltd. (正大天晴藥業集團股份有限公司), a subsidiary of Sino Biopharmaceutical Limited (stock code: 1177) (together with its subsidiaries, the “**Sino Biopharmaceutical Group**”), and Akeso Biopharma, Inc. (“**Akeso Biopharma**”), the purpose of which is to jointly develop

the recombinant humanized anti PD-1 monoclonal antibody AK105 and strive to promote the registration, launch and commercialization of the drug.

About AXL inhibitor

AXL inhibitor is a highly selective, oral, small molecule product. As a member of the TAM (Tyro3, AXL and Mer) family of tyrosine protein kinases, AXL, along with its ligand GAS6, is highly expressed and activated in many malignant tumors. The GAS6-AXL signaling pathway, as one of the crucial signaling pathways promoting tumor growth and metastasis, tumor immune escape and drug resistance, is considered to be a new target for cancer treatment. The product is currently in the phase I/II clinical studies in North America.

About Penpulimab PD-1 monoclonal antibody

Penpulimab PD-1 monoclonal antibody product is co-developed by the Sino Biopharmaceutical Group and Akeso Biopharma, and has been granted marketing approval by the National Medical Products Administration of China (the “NMPA”), for the treatment of patients with relapsed or refractory classic Hodgkin’s lymphoma after at least second-line systemic chemotherapy treatment.

About Xuanzhu Biopharm

Xuanzhu Biopharm is the innovative drug research subsidiary of Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetic group. After nearly 10 years of construction and development, the company has gathered an outstanding team of nearly 400 led by returned scientists. The company owns the ability to research and develop innovative drugs independently, forms a complete R&D system, with complete drug development and industrialization capabilities, and does not rely on license-in and CRO, with the ability to innovate and produce continuously. Xuanzhu Biopharm owns two first-class innovative drug R&D platforms for both small molecular and large molecular, and is dedicated to the development of category 1.1 innovative drugs for small molecular and bio-macromolecular. It currently has more than 25 innovative drugs in pipeline under development, focusing on tumors, metabolism, digestion, and other fields. Among them, Xuanzhu Biopharm has a full coverage on major targets of breast cancer, and thus becomes one of the companies in China with the most comprehensive coverage in breast cancer therapeutic areas. The R&D of Xuanzhu Biopharm is progressing rapidly, with the NMPA accepting its NDA for Anaprazole Sodium for the treatment of duodenal ulcer. In addition, it has nearly 10 products in clinical stage. The pipeline layout is complete and balance in long, medium, and short terms, with strong capability to innovate continuously, in order to ensure that at least 1–2 products could apply for IND every year in the future. Riding on the commercialization capabilities of its parent company Sihuan Pharmaceutical, Xuanzhu Biopharm is now transforming from a Biotech company to a Biopharm company, and is gradually becoming a company with excellent R&D and industrialization capabilities.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical enterprise led

by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 30 May 2022

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.